Opportunity Information: Apply for PA 07 167
Apply for PA 07 167
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Functional Genetics and Genomics of Drug Addiction (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279 Drug Abuse and Addiction Research Programs.
- This funding opportunity was created on Dec 5, 2008 and posted on Dec 14, 2006.
- Applicants must submit their applications by Multiple Receipt Dates See Link to Full Announcement for details.. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- Eligible applicants include: Small businesses Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses State governments Public and State controlled institutions of higher education City or township governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education Special district governments Native American tribal governments (Federally recognized) Others (see text field entitled Additional Information on Eligibility for clarification) Independent school districts County governments.
- Foreign institutions are eligible to apply. Eligible agencies of the Federal Government can apply. Faith based or community based organizations can apply.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIH funding opportunity PA-07-167, titled Functional Genetics and Genomics of Drug Addiction (R21), supports early stage, exploratory research aimed at moving beyond gene discovery and into gene function in the context of addiction. The central idea is that human and animal genetic and genomic studies have already produced many candidate genes and specific gene variants that appear to influence addiction risk or addiction-related behaviors, but identifying candidates is only the beginning. This program is designed to fund studies that test which candidates truly play a causal or biologically meaningful role in addictive processes, and then to dig into how they work at a molecular and cellular level.
The scientific focus is explicitly on basic functional genomics in two broad, connected areas. First, it encourages functional validation work that helps separate real addiction-relevant genes or variants from those that are merely correlated signals from discovery studies. This can include experiments that directly test whether changing a gene, its expression, or a specific variant alters addiction-related phenotypes or biological responses tied to drug exposure, reward, craving, tolerance, withdrawal, or relapse vulnerability. Second, it promotes detailed mechanistic studies that map the molecular pathways, networks, and biological processes modulated by these genes or variants. A particular emphasis is placed on cases where a candidate gene appears to have an unexpected or unanticipated role in addiction, since those findings can uncover new biology and open up novel prevention or treatment directions.
The award mechanism is the NIH Exploratory/Developmental Grant (R21), which is typically used for innovative, higher risk, or proof-of-concept projects that can generate strong preliminary data for larger studies. This announcement is described as running in parallel with companion opportunities of the same scientific scope: PA-07-166, which uses the R01 mechanism for more mature, fully developed projects, and PA-07-168, which uses the smaller R03 mechanism. In other words, the topic area is consistent across the three announcements, but the scope, budget, and typical maturity of the proposed work should match the mechanism.
Budget and timing are tightly defined. Projects may last no more than two years total. Direct costs are capped at $275,000 across the two-year period, and no single year may request more than $200,000 in direct costs. The R21 under this FOA is not renewable, which signals that applicants should treat it as a time-limited development effort, ideally positioning the work for subsequent, larger-scale funding if the approach proves successful. The number of awards is not pre-set; awards depend on available funds and on how many applications are judged meritorious in peer review.
Eligibility is broad and includes a wide range of domestic and international institutions and organization types. Eligible applicants include public and private institutions of higher education (including Hispanic-serving institutions, HBCUs, tribally controlled colleges and universities, and Alaska Native and Native Hawaiian-serving institutions), nonprofit organizations both with and without 501(c)(3) status, for-profit organizations (including small businesses), and multiple levels of government (state, local, tribal, U.S. territories and possessions, and eligible federal agencies). Foreign (non-U.S.) organizations are also eligible to apply, and the announcement notes that faith-based or community-based organizations may apply as well, provided they meet applicable requirements.
Administratively, this is a discretionary grant program under the NIH, aligned with CFDA 93.279 (Drug Abuse and Addiction Research Programs). There is no cost-sharing or matching requirement. The opportunity was originally posted in December 2006 and used multiple receipt dates (rather than a single deadline), with applicants directed to the full NIH Guide announcement for the specific submission cycles and instructions. The archive date listed is February 2, 2010, which indicates it is no longer an active solicitation in its original form, though the scientific theme continues to appear in later NIH/NIDA funding opportunities.
In practical terms, the FOA is meant for teams that already have credible candidate genes or variants from genetic association studies, linkage, GWAS, expression profiling, or other genomic screens, and now need to run rigorous functional experiments to confirm relevance and uncover mechanism. The best fit proposals are likely to be tightly scoped, hypothesis-driven or strong discovery-to-function projects that can be executed within two years, producing clear functional evidence and pathway-level insight that advances understanding of addiction biology.
FAQs: NIH PA-07-167 - Functional Genetics and Genomics of Drug Addiction (R21)
What is the NIH funding opportunity PA-07-167?
PA-07-167 is an NIH Funding Opportunity Announcement (FOA) titled Functional Genetics and Genomics of Drug Addiction (R21). It supports early-stage, exploratory projects that move beyond identifying candidate addiction-related genes and variants and instead test whether they are truly functionally important and, if so, how they work biologically.
What is the main purpose of this FOA?
The central goal is to fund research that transitions from gene discovery (finding candidate genes/variants) to functional validation and mechanistic understanding in the context of drug addiction. The FOA is built on the idea that many candidate genes have already been produced by human and animal genetic/genomic studies, and now the field needs rigorous work to identify causal or biologically meaningful candidates and map the pathways they influence.
What kinds of research does PA-07-167 emphasize?
The FOA explicitly focuses on basic functional genomics in two connected areas:
- Functional validation: experiments that distinguish true addiction-relevant genes/variants from signals that are only correlated with addiction-related outcomes in discovery studies.
- Mechanistic studies: research that defines the molecular pathways, networks, and cellular processes modulated by addiction-related genes/variants.
What does "functional validation" mean in this FOA?
Functional validation refers to studies that directly test whether changing a candidate gene, its expression, or a specific variant produces meaningful effects on addiction-related phenotypes or biological responses. The FOA gives examples of relevant addiction-linked outcomes such as responses tied to drug exposure, reward, craving, tolerance, withdrawal, and relapse vulnerability.
What does "mechanistic studies" mean here?
Mechanistic studies are meant to go deeper than confirmation and explain how a validated gene or variant influences addiction biology. This includes mapping downstream pathways, identifying networks and processes affected, and describing molecular and cellular mechanisms involved.
Does the FOA prioritize any particular scientific angle?
Yes. A particular emphasis is placed on cases where a candidate gene appears to have an unexpected or unanticipated role in addiction. The FOA frames these as especially valuable because they can uncover new biology and point toward novel prevention or treatment directions.
What grant mechanism does PA-07-167 use?
PA-07-167 uses the NIH Exploratory/Developmental Grant (R21) mechanism, which is typically intended for innovative, higher-risk, or proof-of-concept work designed to generate strong preliminary evidence for future, larger studies.
How is this R21 FOA related to other announcements?
This FOA is described as running in parallel with companion opportunities that share the same scientific scope:
- PA-07-166 (R01) for more mature, fully developed projects
- PA-07-168 (R03) for smaller projects
The topic area is consistent across the three, but the proposed scope, budget, and maturity are expected to match the specific mechanism (R21 vs R01 vs R03).
What is the maximum project period?
Projects may last no more than two years total under this FOA.
What are the budget limits for this R21?
The FOA caps direct costs at $275,000 total across the two-year project period. In addition, no single year may request more than $200,000 in direct costs.
Is the R21 award under this FOA renewable?
No. The FOA states that the R21 under this announcement is not renewable. It is positioned as a time-limited developmental effort that can set up subsequent, larger-scale funding if successful.
How many awards will NIH make under this FOA?
The number of awards is not pre-set. Awards depend on available funds and on how many applications are judged meritorious through peer review.
Who is eligible to apply?
Eligibility is broad and includes a wide range of domestic and international organizations. Eligible applicants include:
- Public and private institutions of higher education, including Hispanic-serving institutions, HBCUs, tribally controlled colleges and universities, and Alaska Native and Native Hawaiian-serving institutions
- Nonprofits (with or without 501(c)(3) status)
- For-profit organizations (including small businesses)
- State, local, tribal, territorial governments, and eligible federal agencies
- Foreign (non-U.S.) organizations
- Faith-based or community-based organizations (if they meet applicable requirements)
Are foreign (non-U.S.) organizations allowed to apply?
Yes. The FOA explicitly notes that foreign organizations are eligible to apply.
Is cost sharing or matching required?
No. The FOA states there is no cost-sharing or matching requirement.
What federal program area does this FOA fall under?
It is an NIH discretionary grant program aligned with CFDA 93.279 (Drug Abuse and Addiction Research Programs).
When was this FOA posted, and is it still active?
The FOA was originally posted in December 2006 and used multiple receipt dates rather than a single deadline. The archive date is listed as February 2, 2010, indicating it is no longer active in its original form, even though the scientific theme continues to appear in later NIH/NIDA opportunities.
Did this FOA have a single application deadline?
No. The FOA used multiple receipt dates and directed applicants to the full NIH Guide announcement for specific submission cycles and instructions.
What stage of research is the best fit for this opportunity?
The FOA is meant for early stage, exploratory work, particularly where teams already have credible candidate genes or variants from genetic association studies, linkage, GWAS, expression profiling, or other genomic screens and now need to run functional experiments to confirm relevance and uncover mechanism.
What makes a project a strong fit given the R21 constraints?
Based on the FOA description, strong-fit proposals are likely to be tightly scoped and feasible within two years, with a clear plan to produce functional evidence (showing whether a candidate matters biologically) and pathway-level insight (showing how it matters) for addiction-related processes.
Does the FOA focus on gene discovery?
No. The FOA is explicitly designed to move beyond gene discovery. It assumes many candidates already exist and prioritizes studies that validate functional relevance and define mechanism.
What addiction-related outcomes are mentioned as relevant to test?
The FOA references addiction-related phenotypes and biological responses tied to drug exposure, reward, craving, tolerance, withdrawal, and relapse vulnerability as examples of outcomes that could be used in functional tests.
What is the practical intent of the R21 in this program?
The R21 is framed as a way to support innovative, potentially higher-risk development work that can generate convincing evidence and preliminary data, ideally positioning the research for subsequent, larger-scale funding if the approach proves successful.
Browse more opportunities from the same category: Education Health
Next opportunity: Epidemiological and Behavioral Research in Oral Health (R01)
Previous opportunity: Functional Genetics And Genomics Of Drug Addiction (R03)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 07 167
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 07 167) also looked into and applied for these:
| Funding Opportunity |
|---|
| Functional Genetics And Genomics Of Drug Addiction (R01) Apply for PA 07 166 Funding Number: PA 07 166 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Pathogenesis And Treatment Of Lymphedema And Lymphatic Diseases (R01) Apply for PA 07 165 Funding Number: PA 07 165 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Studies of Energy Balance and Cancer in Humans (R01) Apply for PA 07 176 Funding Number: PA 07 176 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Memory T Lymphocytes in Cancer Immunology (R01) Apply for PA 07 255 Funding Number: PA 07 255 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Cancer Surveillance Using Health Claims Based Data (R01) Apply for PA 07 254 Funding Number: PA 07 254 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Information Technologies and the Internet in Health Services and Intervention Delivery (R01) Apply for PA 07 295 Funding Number: PA 07 295 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Epigenetic Approaches in Cancer Epidemiology (R21) Apply for PA 07 299 Funding Number: PA 07 299 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Epigenetic Approaches in Cancer Epidemiology (R01) Apply for PA 07 298 Funding Number: PA 07 298 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Drug Abuse Aspects of HIV/AIDS (R21) Apply for PA 07 309 Funding Number: PA 07 309 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Drug Abuse Aspects of HIV/AIDS (R03) Apply for PA 07 308 Funding Number: PA 07 308 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Drug Abuse Aspects of HIV/AIDS (R01) Apply for PA 07 307 Funding Number: PA 07 307 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Research on Clinical Decision Making in Life Threatening Illness (R21) Apply for PA 07 316 Funding Number: PA 07 316 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Early Career Award in Chemistry of Drug Abuse and Addiction (ECHEM) NIDA (R03) Apply for PAS 07 327 Funding Number: PAS 07 327 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Drug Abuse, Risky Decision Making and HIV/AIDS (R03) Apply for PAS 07 326 Funding Number: PAS 07 326 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Drug Abuse, Risky Decision Making and HIV/AIDS (R01) Apply for PAS 07 324 Funding Number: PAS 07 324 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Drug Abuse, Risky Decision Making and HIV/AIDS (R21) Apply for PAS 07 325 Funding Number: PAS 07 325 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Academic Industrial Partnerships for Development and Validation of In Vivo Imaging Systems and Methods for Cancer Investigations (R01) Apply for PAR 07 214 Funding Number: PAR 07 214 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NIDA Research Education Grants in Drug Abuse and Addiction (R25) Apply for PAR 07 221 Funding Number: PAR 07 221 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Neuroscience Research on Drug Abuse (R01) Apply for PA 07 226 Funding Number: PA 07 226 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Neuroscience Research on Drug Abuse (R21) Apply for PA 07 227 Funding Number: PA 07 227 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 07 167", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.